secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0000950170-23-053108
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical prelim Q3 rev $30.4M (+9% YoY); FY23 guidance cut to ~$130M on FDA letter headwind
--------------------------------------------------------------------------------

- Preliminary Q3 revenue $30.4M (+9% YoY), gross margin 23.6% (25.6% non-GAAP).
- FY23 revenue guidance lowered to ~$130M, citing FDA warning letter impact and cautious capex outlook.
- Cash and investments $197M as of Sept. 30, 2023.
- CEO notes no deal losses but headwinds expected into Q4; confidence in long-term growth and profitability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000095017023053108/0000950170-23-053108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000095017023053108/om-20231012.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer